Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
- Autores
- Sánchez, A.; Brun, L. R.; Salerni, H.; Costanzo, P. R.; González, D.; Bagur, A.; Oliveri, B.; Zanchetta, M. B.; Farías, V.; Maffei, L.; Premrou, V.; Mansur, José Luis; Larroudé, M. S.; Sarli, M. A.; Rey, P.; Ulla, M. R.; Pavlove, M. M.; Karlsbrum, S.; Brance, M. L.
- Año de publicación
- 2016
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BPprior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMDand decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
Facultad de Ciencias Médicas - Materia
-
Medicina
denosumab
bone mineral density
bone turnover markers
osteoporosis - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- http://creativecommons.org/licenses/by/4.0/
- Repositorio
- Institución
- Universidad Nacional de La Plata
- OAI Identificador
- oai:sedici.unlp.edu.ar:10915/151985
Ver los metadatos del registro completo
id |
SEDICI_0345601ab111c7755ae6708fa6906366 |
---|---|
oai_identifier_str |
oai:sedici.unlp.edu.ar:10915/151985 |
network_acronym_str |
SEDICI |
repository_id_str |
1329 |
network_name_str |
SEDICI (UNLP) |
spelling |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with OsteoporosisSánchez, A.Brun, L. R.Salerni, H.Costanzo, P. R.González, D.Bagur, A.Oliveri, B.Zanchetta, M. B.Farías, V.Maffei, L.Premrou, V.Mansur, José LuisLarroudé, M. S.Sarli, M. A.Rey, P.Ulla, M. R.Pavlove, M. M.Karlsbrum, S.Brance, M. L.Medicinadenosumabbone mineral densitybone turnover markersosteoporosisThe aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BPprior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMDand decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.Facultad de Ciencias Médicas2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/151985enginfo:eu-repo/semantics/altIdentifier/issn/2090-8059info:eu-repo/semantics/altIdentifier/issn/2042-0064info:eu-repo/semantics/altIdentifier/doi/10.1155/2016/8738959info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-03T11:11:14Zoai:sedici.unlp.edu.ar:10915/151985Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-03 11:11:14.663SEDICI (UNLP) - Universidad Nacional de La Platafalse |
dc.title.none.fl_str_mv |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
title |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
spellingShingle |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis Sánchez, A. Medicina denosumab bone mineral density bone turnover markers osteoporosis |
title_short |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
title_full |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
title_fullStr |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
title_full_unstemmed |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
title_sort |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
dc.creator.none.fl_str_mv |
Sánchez, A. Brun, L. R. Salerni, H. Costanzo, P. R. González, D. Bagur, A. Oliveri, B. Zanchetta, M. B. Farías, V. Maffei, L. Premrou, V. Mansur, José Luis Larroudé, M. S. Sarli, M. A. Rey, P. Ulla, M. R. Pavlove, M. M. Karlsbrum, S. Brance, M. L. |
author |
Sánchez, A. |
author_facet |
Sánchez, A. Brun, L. R. Salerni, H. Costanzo, P. R. González, D. Bagur, A. Oliveri, B. Zanchetta, M. B. Farías, V. Maffei, L. Premrou, V. Mansur, José Luis Larroudé, M. S. Sarli, M. A. Rey, P. Ulla, M. R. Pavlove, M. M. Karlsbrum, S. Brance, M. L. |
author_role |
author |
author2 |
Brun, L. R. Salerni, H. Costanzo, P. R. González, D. Bagur, A. Oliveri, B. Zanchetta, M. B. Farías, V. Maffei, L. Premrou, V. Mansur, José Luis Larroudé, M. S. Sarli, M. A. Rey, P. Ulla, M. R. Pavlove, M. M. Karlsbrum, S. Brance, M. L. |
author2_role |
author author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
Medicina denosumab bone mineral density bone turnover markers osteoporosis |
topic |
Medicina denosumab bone mineral density bone turnover markers osteoporosis |
dc.description.none.fl_txt_mv |
The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BPprior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMDand decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed. Facultad de Ciencias Médicas |
description |
The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BPprior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMDand decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Articulo http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://sedici.unlp.edu.ar/handle/10915/151985 |
url |
http://sedici.unlp.edu.ar/handle/10915/151985 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/issn/2090-8059 info:eu-repo/semantics/altIdentifier/issn/2042-0064 info:eu-repo/semantics/altIdentifier/doi/10.1155/2016/8738959 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International (CC BY 4.0) |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International (CC BY 4.0) |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:SEDICI (UNLP) instname:Universidad Nacional de La Plata instacron:UNLP |
reponame_str |
SEDICI (UNLP) |
collection |
SEDICI (UNLP) |
instname_str |
Universidad Nacional de La Plata |
instacron_str |
UNLP |
institution |
UNLP |
repository.name.fl_str_mv |
SEDICI (UNLP) - Universidad Nacional de La Plata |
repository.mail.fl_str_mv |
alira@sedici.unlp.edu.ar |
_version_ |
1842260616142651392 |
score |
13.13397 |